Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 16, 2011. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 445,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,185.0 pence per share; lowest price paid was 1,175.5 pence per share.
- Treasury Holdings (Settled): 481,037,284 shares (8.48% of total issued share capital).
- Treasury Holdings (Including Unsettled): 482,332,284 shares (9.29% of total voting rights).
- Shares in Issue (Excluding Treasury): 5,189,748,925 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 445,000 shares on February 16, 2011. These shares are intended to be held in Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 9.29% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The document is a routine disclosure of a share repurchase event.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (481,037,284 settled vs. 482,332,284 including unsettled).
- Confirm the calculation of total voting rights (5,189,748,925 shares in issue excluding Treasury) for disclosure threshold purposes under FSA rules.
- Review the price paid per share (1,175.5 to 1,185.0 pence) against market prices on February 16, 2011.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.